Merck Inc. at Organon investor day outlines the vision and plans for the new company

Merck Inc., hosted on 3 May an Organon management investor day meeting, to detail across women’s health, biosimilars and established brands.The new company will be launched on 3 June 2021 with its headquarters in Jersey City NJ.

A prime product is contraceptive implant Nexplanon (etomogestrel implant) that delivered approximately $1.6 billion in 2020. The biosimilars will include Renflexis (infliximab-abda) in the US, Aybintio (bevacizumab biosimilar) in the EU and Hadlima (adalimumab -bwwd) in Canada and for anticipated launch in the US in 2023.

The Established Brands business consists of 49 products across a range of therapeutic areas, including respiratory, cardiovascular, dermatology and non-opioid pain, and delivered $4.5 billion of revenue in 2020. This portfolio includes brands beyond their patent loss in most markets, with only modest remaining LOE exposure beyond 2021. The company will look to capitalize on these well-known and recognizable brands in international markets by selectively increasing commercial spend in areas that have the potential to offer solid returns..